DelSiTech has signed a collaboration agreement with Orion Corporation. The agreement enables Orion to apply the unique and proprietary DelSiTech® drug delivery technology in combination with its drug molecules for different therapeutic purposes. DelSiTech will receive fully allocated payments for project work and also milestone payments tied to the progress of possible development projects. The agreement contains also an option for licensing and further collaboration.

Dr. Harry Jalonen, CEO of DelSiTech said: “We are proud to have been chosen by Orion as a partner for the development of new innovative drug delivery products. This agreement